Saffron extract research: The science behind two markers.

How crocins and safranal, the two characterized compounds in Saffrion 42™ saffron extract, are studied in preclinical research, and what placebo-controlled trials of a different saffron extract have reported so far.

Two compounds, two pathways.

Saffrion 42™ pairs two characterized saffron compounds in one extract. Preclinical research points to complementary pathways.

Saffrion 42™ contains crocins, studied in preclinical research for the serotonergic pathway with emotional tone as the research target, and safranal, studied for the GABAergic pathway with calm as the research target.

Crocins

Serotonergic pathway

Studied for interaction with serotonergic signalling, including serotonin availability. Preclinical models also explore neuroplasticity signalling and antioxidant activity.

Safranal

GABAergic pathway

Associated in preclinical research with modulation of GABAergic activity, linked to the relaxation response and neural excitability balance.

One standardized extract, two complementary research targets: emotional tone and calm.

Mechanistic descriptions summarize preclinical literature. They are not health claims for the ingredient or for finished products.

What saffron research has shown.

Placebo-controlled trials with a different saffron extract found improvements in some measures of mood, stress and sleep. They provide background for the category, not evidence for Saffrion 42™ itself.[1][2][3]

Read more: what the clinical trials show · saffron extract and sleep

  1. 2017Mood
    Population
    Healthy adults
    Protocol
    Double-blind, placebo-controlled, 4 weeks
    Finding
    Improved mood scores vs. placebo
    [1] Kell et al., 2017. PMID 28735826 (opens PubMed in a new tab)
  2. 2020Sleep
    Population
    Adults with poor sleep (55 of 63 analysed)
    Protocol
    28 mg/day for 28 days
    Finding
    Improvement in sleep measures
    [2] Lopresti et al., 2020. PMID 32056539 (opens PubMed in a new tab)
  3. 2025Mood
    Population
    202 adults with subclinical depressive symptoms
    Protocol
    28 mg/day for 12 weeks
    Finding
    Advantage on the depression measure; no difference on the overall secondary measures
    [3] Lopresti et al., 2025. PMID 40414301 (opens PubMed in a new tab)
  4. Q1 2027

    A dedicated clinical study of Saffrion 42™

    Planned; results not yet reported. Efficacy, tolerability, dose and time to effect for this extract require dedicated data.

    Results expected Q1 2027

Bring Saffrion 42™ into your range.

Request technical documentation, samples and pricing.